← back to search

Patrick H. Maxwell

University of Cambridge · GB
Area of research
Cancer Research · Molecular Biology
Research interest
Research interests include Cancer, Hypoxia, and Metabolism, High Altitude and Hypoxia, Epigenetics and DNA Methylation, and Renal and related cancers.
h-index
95
citations
55,510
works
385
NIH funding
primary concept
Medicine
email

Recent publications

AI education for clinicians
EClinicalMedicine 2024cited by 70position: middledoi
A spatiotemporal atlas of mouse liver homeostasis and regeneration
Nature Genetics 2024cited by 64position: middledoi
Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Kidney International 2023cited by 131position: middledoi
Spatiotemporal transcriptomic atlas of mouse organogenesis using DNA nanoball-patterned arrays
Cell 2022cited by 1,635position: middledoi
Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity
Nature 2022cited by 1,160position: middledoi
Cell transcriptomic atlas of the non-human primate Macaca fascicularis
Nature 2022cited by 212position: middledoi
Genomic epidemiology of SARS-CoV-2 in a UK university identifies dynamics of transmission
Nature Communications 2022cited by 52position: middledoi
Coagulation factor V is a T-cell inhibitor expressed by leukocytes in COVID-19
iScience 2022cited by 10position: middledoi
Cell transcriptomic atlas of the non-human primate <i>Macaca fascicularis</i>
bioRxiv (Cold Spring Harbor Laboratory) 2021cited by 1position: middledoi
HIF-1α metabolically controls collagen synthesis and modification in chondrocytes
Nature 2019cited by 304position: middledoi
Independence of HIF1a and androgen signaling pathways in prostate cancer
bioRxiv (Cold Spring Harbor Laboratory) 2019cited by 2position: middledoi
Osteocytic oxygen sensing controls bone mass through epigenetic regulation of sclerostin
Nature Communications 2018cited by 124position: middledoi
VHL-Mediated Regulation of CHCHD4 and Mitochondrial Function
Frontiers in Oncology 2018cited by 32position: middledoi
Homozygous p.Ser267Phe in SLC10A1 is associated with a new type of hypercholanemia and implications for personalized medicine
Scientific Reports 2017cited by 55position: middledoi
A functional variant in NEPH3 gene confers high risk of renal failure in primary hematuric glomerulopathies. Evidence for predisposition to microalbuminuria in the general population
PLoS ONE 2017cited by 24position: middledoi
Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition
Nature 2016cited by 575position: middledoi
HIF-1α Promotes Glutamine-Mediated Redox Homeostasis and Glycogen-Dependent Bioenergetics to Support Postimplantation Bone Cell Survival
Cell Metabolism 2016cited by 179position: middledoi
Manifesto for a healthy and health-creating society
The Lancet 2016cited by 16position: middledoi
Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry
Nephrology Dialysis Transplantation 2014cited by 236position: middledoi
Loss of PHD3 allows tumours to overcome hypoxic growth inhibition and sustain proliferation through EGFR
Nature Communications 2014cited by 68position: middledoi
Xenon Treatment Protects Against Cold Ischemia Associated Delayed Graft Function and Prolongs Graft Survival in Rats
American Journal of Transplantation 2013cited by 55position: middledoi
Incidence of End-Stage Renal Disease in the Turkish-Cypriot Population of Northern Cyprus: A Population Based Study
PLoS ONE 2013cited by 20position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

Peter Carmeliet · KU Leuven4 papers (2014–2019)Steve Stegen · KU Leuven3 papers (2016–2019)Geert Carmeliet · KU Leuven3 papers (2016–2019)Sarah‐Maria Fendt · VIB-KU Leuven Center for Cancer Biology2 papers (2016–2019)Anne Y. Warren · University of Cambridge2 papers (2016–2019)Daniel P. Gale · The Royal Free Hospital2 papers (2013–2017)Maxine Tran · The Royal Free Hospital2 papers (2016–2019)Bernard Thienpont · VIB-KU Leuven Center for Cancer Biology2 papers (2016–2018)Riet Van Looveren · KU Leuven2 papers (2016–2019)Guy Eelen · University of Turabo2 papers (2016–2019)Sophie Torrekens · KU Leuven2 papers (2016–2019)Bart Ghesquière · KU Leuven2 papers (2016–2019)Anne‐Theres Henze · KU Leuven1 papers (2014–2014)Jyoti Rai · California Institute for Regenerative Medicine1 papers (2019–2019)Antonio Ramos‐Montoya · Cancer Research UK Cambridge Center1 papers (2019–2019)Charlie E. Massie · Cambridge University Hospitals NHS Foundation Trust1 papers (2019–2019) · 1 papers (2017–2017)Filip Meersman · KU Leuven1 papers (2019–2019)Basma Greef · Cambridge University Hospitals NHS Foundation Trust1 papers (2018–2018)Pedro R. Cutillas · AstraZeneca (United Kingdom)1 papers (2016–2016)